Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Brief Summary: RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known which schedule of temozolomide when given together with radiation therapy is more effective in treating glioblastoma or gliosarcoma.

PURPOSE: This randomized phase III trial is studying two different schedules of temozolomide to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed glioblastoma or gliosarcoma.


Options:
A: Arm Label: Conventional adjuvant TMZ; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concurrent temozolomide, Radiation: Concurrent radiation therapy, Drug: 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle | Arm Label: Dose-dense adjuvant TMZ; Type: EXPERIMENTAL; Interventions: Drug: Concurrent temozolomide, Radiation: Concurrent radiation therapy, Drug: 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle | Arm Label: No adjuvant TMZ (not randomized ); Type: OTHER; Interventions: Drug: Concurrent temozolomide, Radiation: Concurrent radiation therapy | Intervention Type: DRUG; Name: Concurrent temozolomide; Assigned to Arm(s): Conventional adjuvant TMZ, Dose-dense adjuvant TMZ, No adjuvant TMZ (not randomized ) | Intervention Type: RADIATION; Name: Concurrent radiation therapy; Assigned to Arm(s): Conventional adjuvant TMZ, Dose-dense adjuvant TMZ, No adjuvant TMZ (not randomized ) | Intervention Type: DRUG; Name: 100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle; Assigned to Arm(s): Conventional adjuvant TMZ | Intervention Type: DRUG; Name: 75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle; Assigned to Arm(s): Dose-dense adjuvant TMZ
B: Arm Label: Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: temozolomide | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide
C: Arm Label: Arm I (radiation therapy, temozolomide, placebo); Type: ACTIVE_COMPARATOR; Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy, Radiation: Intensity-Modulated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Placebo, Other: Quality-of-Life Assessment, Drug: Temozolomide | Arm Label: Arm II (radiation therapy, temozolomide, bevacizumab); Type: EXPERIMENTAL; Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy, Biological: Bevacizumab, Radiation: Intensity-Modulated Radiation Therapy, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Drug: Temozolomide | Intervention Type: RADIATION; Name: 3-Dimensional Conformal Radiation Therapy; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: RADIATION; Name: Intensity-Modulated Radiation Therapy; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Arm I (radiation therapy, temozolomide, placebo), Arm II (radiation therapy, temozolomide, bevacizumab)
D: Arm Label: Experimental intervention; Type: EXPERIMENTAL; Interventions: Biological: Autologous, tumor lysate-loaded, mature dendritic cells (DC) | Arm Label: Control intervention; Type: OTHER; Interventions: Drug: standard therapy | Intervention Type: BIOLOGICAL; Name: Autologous, tumor lysate-loaded, mature dendritic cells (DC); Assigned to Arm(s): Experimental intervention | Intervention Type: DRUG; Name: standard therapy; Assigned to Arm(s): Control intervention

Answer: A